新辅助化疗、手术与放疗后乳腺癌复发模式及生存预测因素
该回顾性研究纳入416例2008至2015年间接受新辅助化疗、手术及辅助放疗的II/III期乳腺癌患者,中位随访4.7年。5年局部区域复发率、无病生存率和总生存率分别为6.4%、77%和90%,多数复发位于放疗野内;三阴性亚型、III期疾病和非病理完全缓解与较差的无病生存和总生存相关。
要点
- 现代新辅助化疗、手术和放疗后5年局部区域复发率低(6.4%),多数复发在放疗野内。
- 三阴性亚型、III期疾病和非病理完全缓解是不良无病生存和总生存的预测因素。
- 病理完全缓解率为22%,非病理完全缓解与较差结局相关。
核心结论
- 接受现代新辅助化疗、手术和放疗的乳腺癌患者5年局部区域复发风险低,且多数复发位于放疗野内。
- 三阴性亚型、III期疾病和非病理完全缓解与较差的无病生存和总生存相关。
研究设计与样本
- 回顾性 review 了416例2008至2015年间接受新辅助化疗、手术和辅助放疗的II/III期乳腺癌患者数据。
- 采用Kaplan-Meier法计算无病生存和总生存率,采用累积发生率函数(以死亡为竞争风险)估计局部区域复发率,采用Cox回归进行多变量生存分析。
主要发现
- 中位随访4.7年,大多数患者为cT2/3(74%)、cN1(61%),接受乳房切除术(75%)和腋窝清扫(84%)。
- 病理完全缓解率为22%;共发生27例局部区域复发(包括4例孤立性局部区域复发)和89例远处失败。
- 2例患者在术后2个月、辅助放疗前出现局部区域复发;23例可定位复发中,20例位于放疗野内,1例位于野内和野外,2例位于野外。
- 5年局部区域复发率、无病生存率和总生存率分别为6.4%、77%和90%。
临床怎么用
- 对于接受新辅助化疗、手术和放疗的乳腺癌患者,局部区域复发风险较低,多数复发在放疗野内,支持现代综合治疗模式。
- 三阴性亚型、III期疾病和非病理完全缓解患者无病生存和总生存较差,需加强随访和个体化治疗策略。
局限性
- 回顾性研究设计,可能存在选择偏倚和信息偏倚。
- 单中心数据,样本量有限(416例),结论外推需谨慎。
- 中位随访时间4.7年,可能不足以评估长期复发和生存结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Neoadjuvant chemotherapy (NAC) is standard of care for locally advanced breast cancer. There is wide variation in radiation therapy (RT) practice and limited data describing locoregional relapse (LRR) after NAC. We hypothesized a low LRR risk with modern NAC, surgery, and RT and aimed to elucidate patterns of LRR and predictors of disease-free survival (DFS) and overall survival (OS) in these patients. METHODS AND MATERIALS: Data from 416 patients with stage II/III breast cancer treated between 2008 and 2015 with NAC, surgery, and adjuvant RT were reviewed retrospectively. DFS and OS rates were calculated using the Kaplan-Meier method. The LRR rate was estimated using the cumulative incidence function, treating death as a competing risk. Multivariable survival analysis was performed using Cox regression. RESULTS: Median follow-up was 4.7 years. Most patients had cT2/3 (74%) cN1 (61%) disease and underwent mastectomy (75%) and axillary dissection (84%). Pathologic complete response (pCR) was achieved in 22% of patients. There were 27 LRRs (including 4 isolated LRRs) and 89 distant failures. Two patients developed LRR 2 months after surgery, before adjuvant RT. LRR could be mapped in 23 patients: most (20) recurred within the RT field; 1 in- and out-of-field; and 2 out-of-field. Five-year LRR, DFS, and OS were 6.4%, 77%, and 90%, respectively. On multivariable analysis, triple-negative subtype (hazard ratio [HR] 2.82; 95% confidence interval [CI], 1.78-4.47; P < .001), stage III disease (HR 1.72; 95% CI, 1.11-2.69; P = .016), and non-pCR (HR 4.76; 95% CI 2.13-10.0; P < .001) were associated with poor DFS and OS (HR 4.13 [95% CI, 2.21-7.72; P < .001]; HR 1.94 [95% CI, 1.001-3.75; P = .049]; and HR 2.38 [95% CI, 0.98-5.88; P = .055], respectively). CONCLUSIONS: Patients with breast cancer treated with modern NAC, surgery, and RT have a low 5-year LRR risk, with the majority occurring in-field. Triple-negative subtype, stage III disease, and non-pCR were associated with inferior DFS and OS.
引用
- Keilty D, Nezafat Namini S, Swain M, et al. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation. Int J Radiat Oncol Biol Phys. 2020. PMID: 32407932. doi:10.1016/j.ijrobp.2020.04.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。